Cliff Asness's BCRX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 704,291 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $5.49 M, representing 0.00% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BCRX, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 362,175 shares. Largest reduction occurred in Q4 2025, reducing 295,494 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -295,494 | Reduce 29.56% | 704,291 | $7.80 |
| Q3 2025 | -149,009 | Reduce 12.97% | 999,785 | $7.59 |
| Q2 2025 | -52,655 | Reduce 4.38% | 1.15 M | $8.96 |
| Q1 2025 | +362,175 | Add 43.15% | 1.2 M | $7.50 |
| Q4 2024 | +52,047 | Add 6.61% | 839,274 | $7.52 |
| Q3 2024 | +243,986 | Add 44.91% | 787,227 | $7.60 |
| Q2 2024 | +85,871 | Add 18.77% | 543,241 | $6.18 |
| Q1 2024 | +83,426 | Add 22.31% | 457,370 | $5.08 |
| Q4 2023 | +300,427 | Add 408.65% | 373,944 | $5.99 |
| Q3 2023 | +35,429 | Add 93.02% | 73,517 | $7.08 |
| Q2 2023 | -820 | Reduce 2.11% | 38,088 | $7.04 |
| Q1 2023 | +13,916 | Add 55.68% | 38,908 | $8.34 |
| Q4 2022 | +2,432 | Add 10.78% | 24,992 | $11.48 |
| Q3 2022 | -7,357 | Reduce 24.59% | 22,560 | $12.59 |
| Q2 2022 | -26,762 | Reduce 47.22% | 29,917 | $10.60 |
| Q1 2022 | -42,185 | Reduce 42.67% | 56,679 | $16.27 |
| Q4 2021 | -31,209 | Reduce 23.99% | 98,864 | $13.85 |
| Q3 2021 | +22,152 | Add 20.53% | 130,073 | $14.37 |
| Q2 2021 | +46,535 | Add 75.81% | 107,921 | $15.81 |
| Q1 2021 | -960 | Reduce 1.54% | 61,386 | $10.17 |
| Q4 2020 | -41,431 | Reduce 39.92% | 62,346 | $7.44 |
| Q3 2020 | -14,836 | Reduce 12.51% | 103,777 | $3.43 |
| Q2 2020 | +97,744 | Add 468.37% | 118,613 | $4.76 |
| Q1 2020 | -26,780 | Reduce 56.20% | 20,869 | $2.01 |
| Q4 2019 | +21,392 | Add 81.47% | 47,649 | $3.44 |
| Q3 2019 | -17,020 | Reduce 39.33% | 26,257 | $2.86 |
| Q2 2019 | -3,593 | Reduce 7.67% | 43,277 | $3.79 |
| Q1 2019 | +2,185 | Add 4.89% | 46,870 | $8.15 |
| Q4 2018 | +44,685 | New Buy | 44,685 | $8.08 |
| Q2 2018 | -29,043 | Sold Out | 0 | $0.00 |
| Q1 2018 | -24,097 | Reduce 45.35% | 29,043 | $4.79 |
| Q4 2017 | -12,979 | Reduce 19.63% | 53,140 | $4.91 |
| Q3 2017 | +11,797 | Add 21.72% | 66,119 | $5.23 |
| Q2 2017 | +12,571 | Add 30.11% | 54,322 | $5.56 |
| Q1 2017 | +41,751 | New Buy | 41,751 | $8.41 |
| Q3 2016 | -97,873 | Sold Out | 0 | $0.00 |
| Q2 2016 | -26,741 | Reduce 21.46% | 97,873 | $2.84 |
| Q1 2016 | +100,050 | Add 407.30% | 124,614 | $2.83 |
| Q4 2015 | -29,252 | Reduce 54.36% | 24,564 | $10.34 |
| Q3 2015 | +31,760 | Add 144.00% | 53,816 | $11.41 |
| Q2 2015 | -206,579 | Reduce 90.35% | 22,056 | $14.92 |
| Q1 2015 | -246,800 | Reduce 51.91% | 228,635 | $9.03 |
| Q4 2014 | +132,373 | Add 38.59% | 475,435 | $12.16 |
| Q3 2014 | +230,200 | Add 203.97% | 343,062 | $9.78 |
| Q2 2014 | +1,100 | Add 0.98% | 112,862 | $12.75 |
| Q1 2014 | +16,500 | Add 17.32% | 111,762 | $10.58 |
| Q4 2013 | +95,262 | New Buy | 95,262 | $7.60 |
Cliff Asness's BioCryst Pharmaceuticals Investment FAQs
Cliff Asness first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q4 2013, acquiring 95,262 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held BioCryst Pharmaceuticals, Inc. (BCRX) for 47 quarters since Q4 2013.
Cliff Asness's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q1 2025, adding 1,201,449 shares worth $9.01 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 704,291 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $5.49 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 1,201,449 shares, as reported at the end of Q1 2025.